EpiBone CEO Nina Tandon discusses stem cell-derived bone and cartilage technology and clinical trial progress
Summary
Nina Tandon, co-founder and CEO of EpiBone, explains the company's technology for growing living bone and cartilage from stem cells as an alternative to metal and plastic joint replacements. She outlines the engineering process involving CT scans, fat-derived stem cells, and bioreactors. Tandon reviews the company's 12-year history and current community funding efforts. She details clinical trial results, including a Phase 1/2 trial at the Cleveland Clinic and San Francisco VA, and future trials for tooth retention, knee replacement, and injectable cartilage. Tandon also discusses the FDA's regulatory landscape and her advocacy for modernization.
Key takeaways
- 1 EpiBone's technology grows living bone and cartilage from stem cells, contrasting with metal and plastic joint replacements.
Nina Tandon · 0:02
Episode sections
- 0:02 – 1:14
Introduction and Technology Overview
Nina Tandon introduces EpiBone's technology of growing living bone and cartilage from stem cells, contrasting it with metal and plastic joint replacements. She explains the engineering process involving CT scans, fat-derived stem cells, and bioreactors that mimic bodily conditions over three to four weeks.
- 1:14 – 7:51
Company Background and Mission
Tandon describes her background as an electrical engineer turned biomedical engineer and co-founder of EpiBone. She discusses the company's 12-year history, its origins in academia, and the current community funding round.
- 7:51 – 10:56
Clinical Trial History and FDA Status
Tandon details the Phase 1/2 trial with six patients at the Cleveland Clinic and San Francisco VA, noting successful integration of jawbone grafts. She outlines future trials: a US Air Force-funded extension for tooth retention, a knee replacement trial cleared in 2023, and an injectable cartilage trial in Thailand cleared in fall 2023.
- 10:56 – 26:46
Regulatory Landscape and Platform Strategy
Tandon discusses the FDA's piecemeal approval process for platform technologies and her advocacy for regulatory modernization. She explains the strategic decision to offer both custom facial bone grafts and off-the-shelf cartilage products to balance customization with surgical urgency.
- 26:46 – 27:58
Investor Message and Conclusion
Tandon addresses investor hype in the biotech space, asserting that EpiBone's science is real and moving from science fiction to reality. She invites investors to share their personal health experiences to foster connection and support.
Claims worth verifying
EpiBone's technology uses a CT scan and a small sample of the patient's own fat to extract stem cells, which are grown on a scaffold for three to four weeks in a bioreactor.
Chris Lustrino ·0:20
How to verify: Company website or white papers describing the manufacturing process; patent filings for scaffold design and bioreactor methods. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceSix patients have had part of their jaw rebuilt using EpiBone's grafts in a clinical trial.
Chris Lustrino ·0:40
How to verify: Clinical trial results published in peer-reviewed journals or press releases from EpiBone/Cleveland Clinic/VA. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The FDA cleared a second trial for the knee in 2023.
Chris Lustrino ·0:40
How to verify: FDA Investigational New Drug (IND) clearance announcements or press releases from EpiBone dated 2026. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone's community round starts at $250.
Chris Lustrino ·0:40
How to verify: KingScrowd.com investment page for EpiBone showing minimum investment amount. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone is a biomedical engineering company founded by Nina Tandon, who has a background in electrical engineering and computer science.
Unidentified speaker (UNKNOWN) ·1:14
How to verify: EpiBone leadership bios on company website; LinkedIn profiles; MIT alumni records. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone completed a six-patient Phase 1/2 trial with the Cleveland Clinic and San Francisco VA, showing bones fit perfectly with no adverse events and integration after four to six months.
Nina Tandon ·8:31
How to verify: Published clinical study results in medical journals (e.g., Journal of Craniofacial Surgery); FDA clinical trial databases. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone is conducting a Phase 2 extension with the US Air Force to prove jawbone can hold a tooth.
Nina Tandon ·9:54
How to verify: US Air Force research grant announcements; EpiBone press releases regarding military funding. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone received FDA greenlight in 2023 for a living partial knee replacement trial.
Nina Tandon ·10:14
How to verify: FDA IND clearance records for EpiBone's knee indication; company press releases from 2026. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
EpiBone received FDA greenlight in fall 2023 for a third trial in Thailand for an injectable cartilage version.
Unidentified speaker (UNKNOWN) ·10:29
How to verify: FDA IND clearance records; Thai regulatory authority approvals; EpiBone press releases from late 2026. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
The injectable cartilage has a two-year shelf life.
Nina Tandon ·23:28
How to verify: Product data sheets or stability testing data released by EpiBone; regulatory filings detailing shelf-life studies. For recent events, verify 2026-08-19 through 2026-11-19. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify EpiBone's clinical trial results and patient outcomes from the Phase 1/2 trial at the Cleveland Clinic and San Francisco VA.
- Check the status and results of the US Air Force-funded tooth retention trial.
- Review the FDA clearance documents for the 2023 knee replacement trial and the fall 2023 injectable cartilage trial in Thailand.
- Assess the regulatory landscape for platform technologies and potential impacts of FDA modernization efforts.
- Evaluate EpiBone's community funding round details and investor terms.
- Research the competitive landscape for stem cell-derived bone and cartilage therapies.
- Consider the technical challenges of scaling bioreactor production for three to four week growth cycles.
- Review Nina Tandon's background and EpiBone's academic origins for potential conflicts of interest or biases.
Full transcriptexpand
0:02Unidentified speaker (UNKNOWN): And
0:02Nina Tandon: instead of doing things like joint replacements that are made out of metal and plastic that, you know, are really just given to us because we're replacing a couple millimeters of damaged cartilage, let's use the cells that did that in the first place and repair our bodies every day and use them as an ingredient to make living anatomically precise skeletal replacements.
0:20Chris Lustrino: Welcome to Inside Startup Investing, the only podcast where you can invest in every guest. On this episode, I'm talking with Nina Tandon, co-founder and CEO of EpiBone. EpiBone grows living bone and cartilage from stem cells. For bone, it starts with a CT scan and a small sample of the patient's own fat. A few weeks later, there's a new piece of bone, shaped to fit that one patient. Six people have already had part of their jaw rebuilt this way in a clinical trial, and the FDA has cleared a second. trial for the knee. The round is open to everyone, starting at $250.
0:56Unidentified speaker (UNKNOWN): To
0:56Chris Lustrino: see the full analyst breakdown and discover how you can invest, visit KingScrowd.com. And now, here's my conversation with Nina. Nina, thanks so much for being here today.
1:08Nina Tandon: Thanks for having me. It's a real pleasure.
1:10Unidentified speaker (UNKNOWN): For
1:10Chris Lustrino: those who don't know you, tell us a little bit about your background.
1:14Unidentified speaker (UNKNOWN): Hi.
1:14Nina Tandon: well, I'm known. Um, let's see, I'm Nina Tandon. I'm CEO and co-founder of a company called EpiBone. We make living bone and cartilage from stem cells. And I am not a biologist, but I am a biomedical engineer. And I found myself in biomedical engineering by way of electrical engineering and computer science. So I'm super excited about the moment we find ourselves in today, where there's a real convergence of uh the kind of traditional technologies of electrical engineering and how that's merging with the the future of biology. But that's my background and um and I'm a super excited to be doing a community round of funding for our company and which is I think what what brought us together. Um just worlds colliding. It's a good moment. Yeah.
1:58Chris Lustrino: It sounds like a fascinating technology. Um can you help us understand w when when you say that you're you're creating these these bones out of uh uh stem cells, like what areas are you focused on? What does that really mean?
2:13Nina Tandon: Yeah. Well, you know, just taking a step back, we are all human beings. We are all cellular beings, we are made out of trillions of cells that conspire in many ways to um create and maintain our bodies. And we all started out our life as one cell big, and that cell divided and differentiated to become all of these various parts of our bodies. And all we are doing at EpiBone is really connecting to that biological fact and using it to say, well, look, you know, our our skeletal re skeletal conditions are the number one cause of disability. for military, civilian, animal populations, you name it. Why don't we take the cells that grew our bodies in the first place and repair our bodies every day? And instead of doing things like joint replacements that are made out of metal and plastic that um, you know, are really just given to us because we're replacing a couple of millimeters of damaged cartilage, let's use the cells that did that in the first place and repair. our bodies every day and use them as an ingredient to make living anatomically precise skeletal replacements. So it's, you know, the cells did that in the first place, but our bodies are really complex
3:27cellular environments. And so this is where the engineering kind of comes into play. And we have to do really,
3:34Unidentified speaker (UNKNOWN): you
3:34Nina Tandon: know, we have to trick the cells into thinking they're inside a body. And we do that using engineering techniques of robotic cell culture. So what that means is just like our cells inside our bodies need diet and exercise, the cells outside our body, if we're gonna cultivate them, need that too. So we essentially do fluid handling to mimic the blood supply of the tissue. And people like myself, my background is electrical engineering. I was very interested in the electrical signals. in the body, like in the brain and muscles. Do cells have that too? And in the case of bone and cartilage, we want to take those tissues for a jog. So we actually deliver pulsatile mechanical stimulation to the cells as they grow. So that's really like the engineering part and how the cells make the tissue. It takes us three to four weeks to make bone, cartilage, or joint tissue. And I realize I'm sitting in front of my lettuce grow. Uh, I don't know if you could see that in the background there. I was thinking to myself, it's just like that. You know, it's in many ways we are um
4:39creating systems to cultivate cells um that that that really mirror the types of technologies we've built for, you know, things like hydroponic gardening and and things like that. It's it's it's engineering. We have to be perfect. And then the cells do all the work. That's the real beauty of the of the job.
4:56Chris Lustrino: If we can take a step back in terms of deciding to found EpiBone, you know, were you starting with the problem saying we'd love to solve this and we're scientists, we could figure it out? Or were you starting with an insight of research you were already doing or someone within your network was doing where you said, oh my gosh, we can do this. And then said, Hey, here's the application. to solve it. I'm just curious where you came at it.
5:17Nina Tandon: That's a really good question. You know, because I was an electrical engineer and I came in, I was um 20 years ago a student at MIT, and I came in hot. I was, I would, I thought I wanted to do brain computer interfaces. Um, and I had a motivation for doing that that related to some diseases that run in my family. Um, but I was really interested in one thing. how can we use electrical signals to do better for the body? And then I met my professors who were working on using that type of thinking about electrical signals, but in a completely different way than what I had thought of and what I was aware of. And this is what happens when you become a scientist. You sort of like a lot of times there's that moment where you feel like the kid in the candy store of whoa, I came in with this one idea, but now I have a completely different worldview. And so it was a sense of, well, I had the what if question for my professors who were chemical engineers and biologists. Um, well, what if we used electrical signals in this way? Could we do more? And could we understand more about what makes those cells
6:25tick? So I think it very much. is like science. You stand on the shoulders of giants, and on the other hand, you bring yourself into it, like, and um, and then discover something new. And I think it was um kind of like what you described when we started the company, um, which was we were doing all of this basic science. We'd sort of figured out how what do bone cells like, what are cardiac cells like? And that's really interesting. Um, and then when we started to learn more of those lessons, it translated into what you just said, which is what can we do with this? How do we help people with this? Is it the right company to start now? And 12 years ago we did. We made that leap. We said, look, we've done enough to understand all the kind of boring details around sheer stresses and, you know, all the scientific and engineering kind of parameters that we had to learn. And then it was like, okay, so now let's do do the next step. And that's the been the journey since. I don't think I knew coming in as a scientist that we would end up becoming the entrepreneurs. Um we've gotten used to it now. We're 12 years in. My co-founder and I have been working together now for 20 years.
7:31Soon to be 21. Yeah.
7:34Chris Lustrino: In terms of the development lifecycle of where you are. you know, in terms of getting into market and actually being able to utilize us in patients, where are we? Is there an FDA approval process you have to go through? Have you done tests in real humans? Where are we at on that front?
7:51Nina Tandon: Yeah. So 12 years ago, we spun out of academia. At that point, we had to, we were at horizon one. We had to say, does this technology work you know, in in the bench? Yes. Check. Now let's start the company. Let's make sure that the that the biology works in living systems. So that meant we had to put together all of our FDA applications and and do a bunch of more applied scientific studies. And then in 2019 we got permission to get into human this was a historic moment for us. We got a greenlit by the FDA to do a first in human clinical trial for bone. And we chose craniofacial bone because we wanted to show off that we could make bone in any shape using CT scans from patients. So shape really matters for the face. And we were greenlit by FDA to do a first in human phase one, two clinical trial, which, for those of you who may not know the lingo, phase one is where you prove that your technology is safe, and then you get enough data to then move to a phase two, which allows you to prove more efficacy. Like, does the product work in a small population of people? And then phase three is does it work in the population? And do you have to do a larger study? So we completed
9:05Greenlit in 2019 for our first phase one, two. It was a six-patient Patient phase one, two where we replaced jaw bones in six patients, ranging
9:13Unidentified speaker (UNKNOWN): in
9:13Nina Tandon: age from 18 to 15. 59. We had our 18-year-old waited until his 18th birthday to enroll because he didn't want a piece of his hip cut out to replace his face. So he he had a face some facial asymmetry that we were working to correct. So he waited until uh halfway through his freshman year of college. He was our youngest patient, and 15, we had a 59-year-old. We worked with the Cleveland Clinic face transplant team. This was an amazing process. project. And we worked with the San Francisco VA. And we saw the same thing with all six patients, which is that the bones fit perfectly, no adverse events related to our product. And after about four to six months, the bones integrated and vascularized. So on the heels of that, we applied for military funding, which we are now doing to extend to see if, hey, will that jawbone hold, we want to prove that it holds a tooth? So we're doing that work now with the um US Air Force in a phase two extension. And um we got greenlit by FDA in 2023 to do a living partial knee replacement. So we're laying
10:14layering cartilage on top of the bone so that instead of a partial knee replacement made out of metal or plastic, we can make And that out of cells. So that has been greenlit. Um, and we're raising money for that trial so that. we can begin enrollment. Yeah. Um oh
10:29Unidentified speaker (UNKNOWN): I
10:29Nina Tandon: we have a third trial. Sorry, I need to say that. We were greenlit this fall for a third trial in Thailand to do an injectable version of our cartilage. That's a seven patient uh phase one.
10:39Chris Lustrino: So
10:40Unidentified speaker (UNKNOWN): you
10:41Chris Lustrino: you did this trial with six patients, you're doing these other trials right now. Like how much more do you have to do for the FDA to say, okay. your greenlet to be used
10:53Unidentified speaker (UNKNOWN): in
10:53Chris Lustrino: a widespread way in the medical setting?
10:56Nina Tandon: You know, that no that number is changing as we speak because we are doing significant lobbying work with the FDA. And the FDA has been responsive, I think, to the rallying cry from many founders like myself about the timelines being quite long. Um so I'm I I I'm very happy to say that the FDA has been quite collaborative with us. And we're between two and five years for different parts of our pipeline to get through, you know, projected to get through FDA based on the laws written today. However, there's been a lot of movement at the state level and internationally around biotech. And so we are very hopeful that there will be fully compliant ways. Um, we're not the kind of folks to uh stick our necks out too far that way. We like regulation. Um we think it's really important. Um, and uh but I do I am hopeful that the FDA will continue to be collaborative with companies like us as we think about generation of real world evidence in concert with um late stage clinical trials to speed up some of that time.
12:01Unidentified speaker (UNKNOWN): And
12:01Chris Lustrino: help me understand like like do you need approval to show bone versus cartilage versus maybe something else you
12:08Unidentified speaker (UNKNOWN): need to do?
12:08Chris Lustrino: Or is it like bone and face needs an approval, knee needs an approval, hip needs an approval? Like
12:14Nina Tandon: it's like that. You know, and
12:15Unidentified speaker (UNKNOWN): that's really
12:16Nina Tandon: so so we have different right now the way the FDA works is um because we're a three dimensional therapy and we're also a drug, investigational new drug, because cells are the attribute active ingredient. We we have been asked by the FDA to kind of take a piecemeal approach from a physiology standpoint, which is
12:34Unidentified speaker (UNKNOWN): kind
12:34Nina Tandon: of device-y in a way. But the FDA does have certain new programs that they're putting forward about around platform technologies like ours, so that But we can start to think, um, you know, similarly to cancer, there might, you know, there might be similarities between breast cancer. and skin cancer based on the mutation, but in the past we often thought about skin cancer and breast cancer as being different because they're in different places. Some
12:57Unidentified speaker (UNKNOWN): of
12:58Nina Tandon: those same concepts apply to uh a platform technology like ours. And um so I've been I've been working, um I'm on the board at bio, um, and I've also been um active on the board for Alliance for Regenerative Medicine to do lunch and learns and activities with the um with various parts of the the federal and state governments in the in the US to help lobby for some of these, I think, really good reforms that they're contemplating right now around uh clinical trial modernization. Um, that makes me really excited. I know it's kind of a boring thing, like for some people. It's almost like accounting. Um, but these infrastructural
13:35Unidentified speaker (UNKNOWN): um
13:36Nina Tandon: frameworks uh are are so important. for founders like us. And I think, especially as a scientist coming into this, we can underestimate coming in uh the importance of kind of the operating system of society, which is um that that after the first horizon of preclinical work and the second horizon of proving that your technology works in animals and early clinical trials, we then in this kind of next phase need to think about does our technology work in society? And does it work in the economy? Yeah. Important questions.
14:11Chris Lustrino: Have you found like it just in your own experience going from face
14:16Unidentified speaker (UNKNOWN): to
14:16Chris Lustrino: knee car, like is it a dramatic difference? Or are you finding that it's it's pretty similar? Maybe it's just a little bit of program to say, hey, make the knee instead of the face.
14:26Nina Tandon: That is such a good question. And I think it really speaks to what is a platform technology like ours? So from a technical standpoint, is it really that hard for us to grow cartilage that's needed for, say, a revision rhinoplasty in the nose versus cartilage that's going to be used in the knee? Technically, from our standpoint,
14:52Unidentified speaker (UNKNOWN): I mean,
14:52Nina Tandon: I might get in trouble with my co-founder for saying this, but like it worked on the first try when we said, let's just try growing nose cartilage. And then it worked on the second try again. So it's not like it was beginner's luck. It was like, yes, transferable knowledge.
15:04Unidentified speaker (UNKNOWN): Okay.
15:05Nina Tandon: Um
15:06Unidentified speaker (UNKNOWN): but
15:06Nina Tandon: that would have been that means another three years of uh, you know, to apply to FDA. And so from the
15:12Unidentified speaker (UNKNOWN): the
15:13Nina Tandon: new bottleneck, I think, for platforms. platform technologies, and this also applies in the world of AI. Okay, we can discover drugs faster, but we still are rate limited by testing the biology and living systems, especially humans. Um, and I think that's where the real um where our eyes are gonna start to focus as the next bottleneck here. I think personally that's why we're gonna start to see more and more crowdfunding. Um, we're gonna see more and more people jumping in. because that rate limiting step, I think, if we consider
15:44Unidentified speaker (UNKNOWN): in
15:44Nina Tandon: the context of what's happening on the fundraising environment, I think it's just it's gonna make people thirsty to start proving out that science more. Um that I'm hopeful for what that's gonna mean for releasing some more of those downstream bottlenecks. Um, and I think that's why I so much admire the work you're doing um and that the crowdfunding community. is doing to reach out and build more connections in the biotech community. I think it's I'm super excited to see so many high quality biotech companies starting to make that leap. And it certainly motivated us to do the same.
16:18Chris Lustrino: And if we go back to when you were running that first kind of trial with six patients with with kind of facial bones, you talked about the fact that basically, hey, the body has. taken to it, and you know, that is all very positive. But from a,
16:32Unidentified speaker (UNKNOWN): you
16:32Chris Lustrino: know, customer experience, patient experience, tell me about the outcomes for the patient, how they felt, how they looked. Like, did they walk away saying, Oh my gosh, this is way better than kind of standard of care today?
16:45Nina Tandon: It's such a good question, and I've wanted to know that answer myself as well. Um, because those patients are the six most important people I've never
16:55Unidentified speaker (UNKNOWN): met.
16:57Nina Tandon: And I can also tell you that I only know the names of two of them and that I only learned that very recently because uh that uh there's their surgeon um said that now that it's been five years.
17:09Unidentified speaker (UNKNOWN): I
17:10Nina Tandon: I asked, you know, like she said they they they've had a a a good experience. Would we like to connect with them? And the answer is yes. So um I can't wait to be able to answer that question for you. Um, for them to answer that question
17:23Unidentified speaker (UNKNOWN): for
17:24Nina Tandon: you and for me.
17:25Unidentified speaker (UNKNOWN): Um,
17:26Nina Tandon: but I don't know. And um and it's been a mystery for me. I know that they've been doing well and that's all I know. And um, but I can't wait to to learn more from them and to see how much of their story they want to share. Um and uh we're doing that really carefully with some with with patient advocates who are teaching us how to do this. Um again, as scientists, we got into this because we wanted to help people.
17:53Unidentified speaker (UNKNOWN): And
17:54Nina Tandon: then you asked me to explain phase one, two, three clinical trials. Those are like three and that that put a dozen years between us as scientists to say we're gonna help. people. And um and I got so impatient, you know? And I know that patients are even less patient. Um so I'm excited to be able to answer that question for you soon. Um, because that's um that's really what matters. Um but for privacy concerns, we we haven't been able to ask them directly yet. Yes. Well
18:21Unidentified speaker (UNKNOWN): very simple. I'll ask
18:22Chris Lustrino: one more question on that front. What
18:24Unidentified speaker (UNKNOWN): about
18:24Chris Lustrino: the doctor, their experience working with it? Where they're like, oh my gosh, this is way better.
18:28Unidentified speaker (UNKNOWN): Well,
18:28Nina Tandon: that I can tell you. Um, so we I got to go to and it's almost the fifth anniversary of that, um, November eleventh, um, five years ago when we implanted at the San Francisco VA. And I remember this because we had to close down. The hospital was closed. And so we were doing we were and it was a 14 hour surgery. This was COVID. It was a crazy moment, and we were just reminiscing about this with the surgeon, Dr. Rebecca Silva, who leads the TMJ program, the temporomandibular joint program,
18:56Unidentified speaker (UNKNOWN): um,
18:56Nina Tandon: for the VA. So 14 hour surgery. Okay. We had taken CT scans of this patient whose name I didn't know, and we generated on our side two grafts, one which was a spare just in case, and one just to use in surgery that we had shaped based on the CT scan of that patient. We had taken a 10 ml of fat tissue from that patient that Rebecca mailed to us. We extracted the stem cells out of it. We implanted the stem cells onto a scaffold that we machined using a CT scan, using a a four-axis four axis CNC mill MIL that was like responding to the G code from the CT scan. There was lots of like bits and atoms, okay? The technical challenges here, okay. Those same files were used by a company in Germany called KLS Martin to print surgical guides to tell them exactly where to cut, and all the custom hardware to hold our bone in place,
19:58and to do all of the intermediate steps of of cutting and moving such. that when it came time for Epibone, I think at hour 13, okay, all we did was we Oh, and the scrub nurse, you know, said, Do we need to prep the hip for a bone to be taken out? No, no, no, we did not because we had the bone in a jar. And there was like clapping in the room, you know. But at hour 13, when that bone phame came out to be put in,
20:25Unidentified speaker (UNKNOWN): you know,
20:26Nina Tandon: and there was so were so many of us, and we were all aware of the fact that this was like a historic moment, it fit perfectly. And we all clapped and we were like, this is why we're here. And it was um, it was us, my co-founder and I, the surgical team, the anesthesiologist, the team from that Germany, we were all there. And we all were like, wow, it just worked. Yeah, I I I just that I can tell you. And we pray, you know, that that just like we hypothesized that that would be a better workflow for the patient, we prayed that that would be the case for the patient. So now five years later to come, and we of course we knew from the follow-ups, we knew the technical side of how is the patient doing. Um, but I can't wait to finally meet this, these brave people who you know, did what they needed to do for their own clinical needs, but also gave the gift to science for everybody else who has those same issues. We really felt the weight of
21:26Unidentified speaker (UNKNOWN): that
21:27Nina Tandon: and the gratitude of that. And as a founder, just feeling really grateful that I get the chance to that this is the gig. This is
21:35Unidentified speaker (UNKNOWN): the
21:35Nina Tandon: gig. You get to to do your best and to try, you know, to try and help make the world a better place and just hope that that
21:42Unidentified speaker (UNKNOWN): is
21:42Nina Tandon: true. And you're never alone. Like the teams that you need to collect around you, uh to coalesce, they they it takes a village. Um it was a really big moment for us, and it's um it's about five years out now, almost exactly to the day.
21:55Unidentified speaker (UNKNOWN): Aaron Powell
21:55Chris Lustrino: Are the benefits when we think about the benefits of this technology, right? Obviously, it sounds like you could shape it perfectly to exactly what
22:02Unidentified speaker (UNKNOWN): the
22:02Chris Lustrino: bone would have been. Um, obviously that sounds really powerful, especially in something like the face where you see it. But when I think about like hip bones and things like that, um is the benefit really that this is the natural body? It's not anything, A, that's either coming from somewhere else or B, you know, a piece of metal that will eventually need to be replaced again. Like this is truly just the body. Is that the right way
22:26Unidentified speaker (UNKNOWN): to think
22:26Chris Lustrino: about it? Or is there something that I'm not
22:28Unidentified speaker (UNKNOWN): sure? That's
22:28Nina Tandon: really true. You know, wow, you really hit the nail on the nose. Cause I think you're right. For certain parts of the body, different different aspects of what we do matter more or less. And in the face, we chose that because number one, everyone knows how important it is. And even very small facial asymmetries are are something that we want to make sure to um avoid. Um but in the hip, is that really the case? Can we get away? You know, we know that in the mass-produced hip implant industry that maybe small, medium, large isn't enough. Okay. We know there's a there's other companies that have been really active in that custom space. Um uh but how custom do we need it, right? I think it's there's a there's a spectrum of if the face is the most uh custom, what is the least? So we didn't take the customized approach for cartilage. We said, look, we want something off the shelf. We also know that surgeons, when there's a traumatic injury in a joint, they don't want to wait four weeks. Um, with the with facial reconstruction and with certain elective procedures, you can wait the time to get that perfect fit, that customization. Um, but for certain indications, like for joint repair, the the expectation is that there's a faster turnaround of material. Um but also that there's less customization needed. So we took that approach. We made our cartilage off the shelf. Um, our injectable cartilage has a a two-year shelf life. Um, we're proving
23:48that to be longer over time. Turns out that shelf life studies need to be as long as the shelf life. So um could we'll continue to show you how long that shelf life can be extended, um, but also just in in sizes that we know surgeons are going to want in the OR so that they
24:02Unidentified speaker (UNKNOWN): can.
24:03Nina Tandon: you know, do their customization more in real time with what they've got in front of them. Similarly, for this was a surprise for the rhinoplasty example that I gave you before for nose reconstruction. Do they necessarily want a custom shape designed before they get in the OR? Are? Not as much as you'd expect. So I think this is where we really need to make sure that we have a fast. feedback loop between ourselves and the physicians. And again, that's why we're super stoked about our crowdfunding campaign because it's been a lot of orthopedic surgeons and just people in the healthcare space, a lot of healthcare executives weighing in, um, putting in their dollars and also feeding back to us Um, their requests um as well as their kind of feedback on what we're doing. Um, And I think that that's gonna be how we don't accidentally make something customized that doesn't need to be and it's more expensive than it needs to be, or or doing the opposite thing where we don't customize enough. Yeah.
25:02Chris Lustrino: So if we think two to three years out from now, what does success look like for
25:07Unidentified speaker (UNKNOWN): you?
25:08Nina Tandon: Oh, I can't wait to be able to say we are taking in receipts um on product that's in the wild. Um approved by FDA, being used in the OR. That is something that we absolutely, you know, are gunning for. And I hope that we can say that that's the case for multiple indications, because we want to be able to show that this isn't just a one-trick pony. This is a platform. Um, And then what does success look like for us? Um, Like what does that mean for patients? I think that means that we're gonna be able to give patients and regular people with aches and pains a sense of hope that we're not just on this over the hill downward trajectory with age that I think everybody has sort of accepted as the norm these days. That like, hey, you might get injured at 15 and live till 115, but you just want to make sure you stop running at 30 because you
26:08might get early onset arthritis. I would love to be able to say in a couple of years, no, no, no. All you gotta do, you just gotta get a couple of years away and then hit escape velocity on that whole narrative. Because just like you can replace tires on your car, we can go in there and give you some new cartilage, um, you know, pop a pothole filler for that defect. So that, you know, you may have played soccer in your teenage years and you're gonna live another hundred after that. Um, but your cartilage will too.
26:39Unidentified speaker (UNKNOWN): For
26:40Chris Lustrino: those investors who are on the line, I want to give you the last word. What do you want them to
26:44Unidentified speaker (UNKNOWN): know?
26:46Nina Tandon: I want them to know
26:47Unidentified speaker (UNKNOWN): that
26:48Nina Tandon: there's been a lot of hype in this space and there has been a lot of boats that have crashed on these shores because, like any holy grail, it's a it's a goal worth chasing.
26:58Unidentified speaker (UNKNOWN): Um, what
27:00Nina Tandon: I would like investors to know is that this is science fiction becoming science theft, and it's real. And we want to talk to you about
27:11Unidentified speaker (UNKNOWN): it.
27:11Nina Tandon: Tell us about your aches and pains, investors.
27:14Unidentified speaker (UNKNOWN): I
27:14Nina Tandon: tell you. what, that is the best conversation starter. Because when we start there, we start to give them a window and uh and maybe help them with their aches and pains. And in so doing, helping a lot more people downstream.
27:29Chris Lustrino: Thanks to Nina for joining me. To learn how you can invest in EpiBone, visit KingScrowd.com. And if you want our full analyst take on this deal before you put a dollar in, that's exactly what King's Crowd Edge is for. Remember, every guest on this show is raising. So check out the library for even more content. See you next
27:49Unidentified speaker (UNKNOWN): time.